Compare Mimetogen Pharmaceuticals vs VentiRx Pharmaceuticals
Customers evaluate the quality of Mimetogen Pharmaceuticals's products using the following success metrics.
Overview
Mimetogen Pharmaceuticals is based in Canada
Mimetogen is actively pursuing the development of novel small molecule compounds to treat neurodegenerative diseases of the eye, including dry eye, glaucoma and retinitis pigmentosa. The company designs and develops small molecule drugs that mimic the effects of neurotrophins, proteins that help maintain the health and growth of many cells and tissues found in the eye. Making drugs that can mimic the large natural molecules may lead to the development of novel approaches to treat degenerative ocular diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration and dry eye.
VentiRx Pharmaceuticals is 18 yrs old and is based in United States.
VentiRx Pharmaceuticals is a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases. The company's lead product candidate is motolimod (VTX-2337), a small molecule TLR8 agonist for the treatment of cancer.
Demo Video
Leadership
Martin B. Wax (Chief Executive Officer)
Michael J. Kamdar (Founder)
Funding
Investors
Medwell Capital, Inovia Capital
Celgene, Domain Associates
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Mimetogen Pharmaceuticals has not claimed their profile.
Work for Mimetogen Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Mimetogen Pharmaceuticals?
Claim your profile now.
Information not available because VentiRx Pharmaceuticals has not claimed their profile.
Work for VentiRx Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for VentiRx Pharmaceuticals?
Claim your profile now.